MaxCyte Inc (MXCT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
MaxCyte Inc stock (MXCT) is currently trading at $0.69. MaxCyte Inc PS ratio (Price-to-Sales) is 2.35. Analyst consensus price target for MXCT is $6.07. WallStSmart rates MXCT as Sell.
- MXCT PE ratio analysis and historical PE chart
- MXCT PS ratio (Price-to-Sales) history and trend
- MXCT intrinsic value — DCF, Graham Number, EPV models
- MXCT stock price prediction 2025 2026 2027 2028 2029 2030
- MXCT fair value vs current price
- MXCT insider transactions and insider buying
- Is MXCT undervalued or overvalued?
- MaxCyte Inc financial analysis — revenue, earnings, cash flow
- MXCT Piotroski F-Score and Altman Z-Score
- MXCT analyst price target and Smart Rating
MaxCyte Inc
📊 No data available
Try selecting a different time range
Smart Analysis
MaxCyte Inc (MXCT) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
MaxCyte Inc (MXCT) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
75.99% of shares held by major funds and institutions
Supporting Valuation Data
MaxCyte Inc (MXCT) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -16.40%, a shrinking business
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Revenue is fairly priced at 2.35x sales
MaxCyte Inc (MXCT) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (0.45) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (2.35) suggest expensive pricing. Growth concerns include Revenue Growth at -16.40%, which may limit upside. Profitability pressure is visible in Return on Equity at -23.20%, Operating Margin at -162.40%, Profit Margin at -132.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -23.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -16.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MXCT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MXCT's Price-to-Sales ratio of 2.35x sits near its historical average of 2.43x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 8% below its historical high of 2.54x set in Mar 2026, and 1% above its historical low of 2.33x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for MaxCyte Inc (MXCT) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
MaxCyte Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 34M with 16% decline year-over-year. The company is currently unprofitable, posting a -132.6% profit margin.
Key Findings
Debt-to-equity ratio of 0.10 indicates a conservative balance sheet with 13M in cash.
Spending 15% of revenue (5M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 16% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -132.6% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact MaxCyte Inc.
Bottom Line
MaxCyte Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About MaxCyte Inc(MXCT)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
MaxCyte Inc. (MXCT) is a leading innovator in cell-engineering solutions, renowned for its proprietary Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and proteins across diverse cell types. Catering to a broad spectrum of clients, including major biopharmaceutical companies and research institutions, MaxCyte plays a critical role in the rapidly evolving cell and gene therapy market. The company's advanced platforms are essential for the development of cutting-edge cell-based therapies and vaccines, positioning MaxCyte to capitalize on significant growth opportunities in the healthcare sector. With a steadfast dedication to advancing transformative treatment options, MaxCyte is well-equipped to address the escalating global demand for innovative therapeutic modalities.